This article is part of the supplement: Basic science, rationale, background and future of abatacept
Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
Citation and License
Arthritis Research & Therapy 2005, 7(Suppl 2):S15-S20 doi:10.1186/ar1505Published: 16 March 2005
Rheumatoid arthritis (RA) is a common destructive inflammatory disease that affects 0.5–1% of the population in many countries. Even though several new treatments have been introduced for patients with RA, a considerable proportion of patients do not benefit from these, and the need for alternative treatment strategies is clear. This review explores the potential for a therapy targeting the adaptive immune system by modulating co-stimulation of T cells with a CTLA4–Ig fusion protein (abatacept).